Pathogenesis and management of the dyslipidemia of the metabolic syndrome

Metabolic Syndrome and Related Disorders

Volumn 7, Issue 2, 2009, Pages 83-88

  Raal, Frederick J ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; EZETIMIBE; FATTY ACID; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; RIMONABANT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LOW FAT DIET; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DIET; DYSLIPIDEMIAS; EXERCISE; HUMANS; LIPIDS; LIPOPROTEINS, VLDL; METABOLIC SYNDROME X; POSTPRANDIAL PERIOD; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 66749139008     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2008.0079     Document Type: Review

References (54)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and blood Institute Scientif c Statement. Circulation 2005;112:2735-2752.
2. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007;92:399-404.
3. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998;81:18B-25B.
4. Adiels M, Olofsso n S - O, Taskine n M-R, Boren J. Over production of very low-density lipoproteins is the hallmark of the dyslipi-demia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-1236.
5. Gill JM, Brown JC, Bedford D, Wright DM, Cooney J, Hughes DA, Packard CJ, Caslake MJ. Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis 2004;176:49-56.
6. James RW, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, Farriaux J P, Tacquest A, Demant T, Clegg RJ, et al. Apolipoprotein B metabolism in homozygous familial hyper-cholesterolemia. J Lipid Res 1989;30:159-169.
7. Adeli K, Lewis GF. Intestinal lipoprotein overproduction in insulin-resistant states. Curr Opin Lipidol 2008;19:221-228.
8. Duez H, Lamarche B, Valero R, Pavlic M, Proctor S, Szeto L, Patterson BW, Lewis G. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 2008;117:2369-2376.
9. Pavlic M, Valero R, Duez H, Xiao C, Szeto L, Patterson BW, Lewis G. Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol 2008;28:1-5.
10. Stalenhoef AFH, de Graaf J. Association of fasting and nonfast-ing serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol 2008;19:355-361.
11. Sacks FM, Campos H. Low-Density lipoprotein size and cardiovascular disease: A reappraisal. J Clin Endocrinol Metab 2003;10:4525-4532.
12. Patsch W, Ostlund R, Kuisk I, Levy R, Schonfeld G. Characterization of lipoprotein in a kindred with familial hypercholesterolemia. J Lipid Res 1982;23:1196-1205.
13. Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 2006;17:412-417.
14. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-2033.
15. Pischon T, Girman CJ, Sacks FM, et al. Non high-density lipo-protein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005;112:3375-3383.
16. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003;36:421-429.
17. Fraser R. The role of dietary triglycerides in cholesterol metabolism. Atherosclerosis 1974;19:327-336.
18. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-485.
19. Kolovou DG, Anagnostopoulou K, Pavlidis AN, Salpea KD, Hoursalis IS, Manolis A, et al. Postprandial lipaemia in menopausal women with metabolic syndrome. Maturitas 2006;55:19-26.
20. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106:453-458.
21. Kolovou GD, Anagnostopoulou KK, Pavlidis AN, Salpea KD, Iraklianou SA, Hoursalis IS, et al. Metabolic syndrome and gender differences in postprandial lipemia. Eur J Cardiovasc Prev Rehab 2006;4:661-664.
22. Couillard C, Bergeron N, Prud'homme D, Bergeron J, Tremblay A, Bouchard C, Mauriege P, Despres JP. Gender difference in postprandial lipemia: importance of visceral adipose tissue accumulation. Arterioscler Thromb Vasc Biol 1999;19:2448-2455.
23. Despres J-P, Lemieux I, Bergeron J, Pibarot P, Mathier P, Larose E, Rodes-Cabau J, Bertrand OF, Poirier P. Abdominal obesity and the Metabolic Syndrome: Contribution to Global Cardiometabolic Risk. Arterioscler Thromb Vasc Biol 2008;28: 1039 -1049.
24. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005;2:536-543.
25. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38.
26. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-316.
27. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993-1001.
28. Kovacs P, Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 2005;19:625-635.
29. Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 1997;8:146-153.
30. Koh KK, Han SH, Quon MJ. Role of inf ammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005;46:1978-1985.
31. Mozaffarian D, Wilson PWF, Kannel WB. Beyond established and novel risk factors. Lifestyle risk factors for cardiovascular disease. Circulation 2008;117:3031-3038.
32. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Bluher M, Stumvoll M, Stampfer J. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008;359:229-241.
33. Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS. Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 2000;85:977-982.
34. Marcus BH, Williams DM, Dubbert PM, Sallis JF, King AC, Yancey AK, Franklin BA, Buchner D, Daniels SR, Claytor R P. Physical Act ivity Inter vention Studies. What we k now a nd what we need to know. A Scientif c Statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity); Council on Cardiovascular Disease in the Young; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Circulation 2006;114:2739-2752.
35. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancy AK, Wenger NK. American Heart Association Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity): Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003;107:3109-3116.
36. Robins SJ. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or f brates be f rst line lipid therapy? Curr Opin Lipidol 2003;14:575-583.
37. Farnier M, Picard S. Diabetes: Statins, fibrates, or both? Curr Atherosclerosis Rep 2001;3:19-28.
38. Knopp RH, Paramsothy P, Atkinson B, Dowdy A. Comprehensive lipid management versus aggressive low-density lipopro-tein lowering to reduce cardiovascular risk. Am J Cardiol 2008;101(Suppl):48B-57B.
39. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-696.
40. Devaraj S, Chan E, Jialal I. Direct demonstration of an anti-inf ammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006;91:4489-4496.
41. Abe M, Matsuda M, Kobayashi H, Miyata Y, Nakayama Y, Komuro R, Fukuhara A, Shimomura I. Effects of statins on adipose tissue inf ammation. Arterioscler Thromb Vasc Biol 2008;28:871.
42. Barter PH, Rye K-A. Is there a role for f brates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2008;27:1-8.
43. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Comman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenof brate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005;366:1849-1861.
44. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000;2:36-46.
45. Benyo Z, Gille A, Kero J, Csiky M, et al. GPR 109A (PUMA-G/ HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005;115:3634-3640.
46. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic-acid induced f ushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-630.
47. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. Effects of the PPAR gamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005;115:1323-1332.
48. Riserus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheesman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Wilson T, Hassall D, Frayn KN, Karpe F. Activation of peroxisome proliferator-activated receptor (PPAR) delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008;57:332-339.
49. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myo-cardial infarction: Results of the GISSI-Prevenzione trial. Lancet 1999;354:447-455.
50. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, et al. for the Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007;369:1090-1098.
51. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerabil-ity of simvastatin plus fenof brate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95:462-468.
52. The ACCORD Trial: a multidisciplinary approach to control cardiovascular risk in type 2 diabetes mellitus. Pract Diabetol 2004;23:6-11.
53. United Kingdom Prospective Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
54. John D, Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk. Consensus Conference Report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008;51:1512-1524.